Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Blood
|
January 10, 2015
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Preetesh Jain, Michael Keating, William Wierda, et al.
Cancer
|
April 5, 2023
Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity
Max J Gordon, Jade E Jones, Binsah George, et al.
Journal of the National Cancer Institute
|
January 19, 2018
The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia
Michael J Overman, Renata Ferrarotto, Kanwal Raghav, et al.
Cancer Medicine
|
October 16, 2018
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors
Alejandro Zulbaran-Rojas, Huei-Kan Lin, Qiuling Shi, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Blood
|
January 10, 2015
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Preetesh Jain, Michael Keating, William Wierda, et al.
Cancer
|
April 5, 2023
Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity
Max J Gordon, Jade E Jones, Binsah George, et al.
Journal of the National Cancer Institute
|
January 19, 2018
The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia
Michael J Overman, Renata Ferrarotto, Kanwal Raghav, et al.
Cancer Medicine
|
October 16, 2018
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors
Alejandro Zulbaran-Rojas, Huei-Kan Lin, Qiuling Shi, et al.
Page
of 2